Login to Your Account

Clinic Roundup

Thursday, November 10, 2011
• NeuroDerm Ltd., of Ness Ziona, Israel, reported that ND0611 met all primary and secondary endpoints in a Phase I/II safety and pharmacokinetic trial as an adjunct therapy in advanced Parkinson's disease. The drug is administered subcutaneously by a dermal patch and is designed to increase the bioavailability and efficacy of orally administered levodopa, as in Sinemet, Sinemet CR or Stalevo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription